2017. Maintenance of Response with Certolizumab Pegol for the Treatment of Chronic Plaque Psoriasis: 48-Week Results from Two Ongoing Phase 3, Multicenter, Randomized, Placebo-Controlled Studies (CIMPASI-1 and CIMPASI-2). SKIN The Journal of Cutaneous Medicine. 1, 3.1 (Oct. 2017), s23. DOI:https://doi.org/10.25251/skin.1.supp.22.